Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10920881 | 0.88 | ALDH1A1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27606455 | 0.86 | ALDH1A1 (0.53) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27868404 | 0.85 | MAPT (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL182652 | 0.84 | MAPT (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2698893 | 0.84 | MEN1 (0.61) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL182524 | 0.83 | PLA2G4B (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11842385 | 0.83 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4261703 | 0.83 | MAPT (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7447406 | 0.83 | MAPK1 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6960 | 0.83 | ALDH1A1 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2400968-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2400968-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2010099502-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099502-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, GRIK2 | RAB9A 2764/4885NPC1 2378/4885SMN1; SMN2 3008/4885 |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | RAB9A 2437/4885NPC1 3178/4885SMN1; SMN2 3263/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | RAB9A 3448/4885NPC1 3513/4885SMN1; SMN2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.